Anavex Life Sciences Corp (AVXL)

[boi568]

I am not basing my argument on the fact that AVXL has sponsored the new Sigma 1 research. You seem to have an issue with that, though.

The point is that amyloid plaque treatments are band aid therapies and too many people have too much investment, both financially and professionally, to admit it.

The Sigma 1 biomarker has remarkable significance. It ties together the upstream MOA thesis (by applying equally well to PDD and Rett) with significant clinical effect. There is no reason to expect it will not also apply to AD.

Those companies and individuals committed to the dying amyloid plaque thesis will, metaphorically, be buried alongside it.